Abstract
A case–control study from two randomised breast cancer prevention trials of tamoxifen and raloxifene (P-1 and P-2) identified single-nucleotide polymorphisms (SNPs) in or near genes ZNF423 and CTSO as factors which predict which women will derive most anti-cancer benefit from selective oestrogen receptor modulator (SERM) therapy. In this article, we further examine this question using blood samples from two randomised tamoxifen prevention trials: the International Breast Cancer Intervention Study I (IBIS-I) and the Royal Marsden trial (Marsden). A nested case–control study was designed with 2:1 matching in IBIS-I and 1:1 matching in Marsden. The OncoArray was used for genotyping and included two SNPs previously identified (rs8060157 in ZNF423 and rs10030044 near CTSO), and 102 further SNPs within the same regions. Overall, there were 369 cases and 662 controls, with 148 cases and 268 controls from the tamoxifen arms. Odds ratios were estimated by conditional logistic regression, with Wald 95 % confidence intervals. In the tamoxifen arms, the per-allele odds ratio for rs8060157 was 0.99 (95 %CI 0.73–1.34) and 1.00 (95 %CI 0.76–1.33) for rs10030044. In the placebo arm, the odds ratio was 1.10 (95 %CI 0.87–1.40) for rs8060157 and 1.01 (95 %CI 0.79–1.29) for rs10030044. There was no evidence to suggest that other SNPs in the surrounding regions of these SNPs might predict response to tamoxifen. Results from these two prevention trials do not support the earlier findings. rs8060157 in ZNF423 and rs10030044 near CTSO do not appear to predict response to tamoxifen.
This is a preview of subscription content, log in via an institution to check access.
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. (2012) GLOBOCAN v1.0, Cancer incidence and mortality worldwide: IARC cancerbase No. 11 [Internet]. 2013. Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr, accessed 21 April 2016
Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A et al (2013) Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381:1827–1834
Donnelly LS, Evans DG, Wiseman J, Fox J, Greenhalgh R, Affen J et al (2014) Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Brit J Cancer 110:1681–1687
Ingle JN, Liu M, Wickerham DL, Schaid DJ, Wang L, Mushiroda T et al (2013) Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov 3:812–825
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project p-1 study. J Natl Cancer Inst 90:1371–1388
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA—J Am Med Assoc 295:2727–2741
Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A et al (2002) First results from the international breast cancer intervention study (IBIS-I): a randomised prevention trial. Lancet 360:817–824
Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283–290
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A et al (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16:67–75
Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A et al (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 103:744–752
Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Statist Med 23:1111–1130
Core Team R.(2012): A language and environment for statistical computing. R foundation for statistical computing Vienna. ISBN 3-900051-07-0
Funding
This work was supported by the National Cancer Institute at the National Institute of Health (Grant number prime award: 5U19CA148065-03Rev; sub-award: 114080_5029147 to JC) and Cancer Research UK (Grant number C569/A16891). MD received funding from the Royal Marsden NIHR Biomedical Research Centre. This work was also supported by the Da Costa Foundation for Breast Cancer Prevention.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
JC reports research funding from AstraZeneca. MD reports a consultant/advisory role with Radius, GTx. All other authors declare that they have no conflict of interest.
Ethical standards
The IBIS-I trial was approved by the local ethics committee of each centre. The Marsden trial was approved by the Royal Marsden Hospital ethics committee. They are registered at controlled-trials.com as ISRCTN91879928 (IBIS-I) and ISRCTN07027313 (Marsden).
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Brentnall, A.R., Cuzick, J., Byers, H. et al. Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. Breast Cancer Res Treat 158, 591–596 (2016). https://doi.org/10.1007/s10549-016-3885-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-016-3885-x